HI
RVNC

HBK Investments’s Revance Therapeutics, Inc. RVNC Stock Holding History

HBK Investments’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,000
Closed -$405K – 234
2022
Q3 		$405K Buy
+15,000
New +$304K ﹤0.01% 392

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HBK Investments's RVNC Position: Q4 2022 in Review

HBK Investments sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 15,000 shares — an estimated $405K sold.

HBK Investments first reported a position in RVNC in Q3 2022 and held it in 1 quarter. The position peaked at $405K in Q3 2022. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

  • HBK Investments reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
  • HBK Investments sold 15,000 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $405K.
  • HBK Investments first reported a position in Revance Therapeutics, Inc. in Q3 2022 and held it in 1 quarter.
  • HBK Investments's Revance Therapeutics, Inc. position peaked at $405K in Q3 2022.
  • 193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on HBK Investments's 13F filing for Q4 2022, filed 14 Feb 2023.